Bank of America Boosts DaVita (NYSE:DVA) Price Target to $145.00

DaVita (NYSE:DVA) had its target price increased by Bank of America from $139.00 to $145.00 in a research note published on Wednesday, Benzinga reports. The brokerage currently has an underperform rating on the stock.

A number of other research analysts have also issued reports on DVA. Barclays upped their target price on shares of DaVita from $133.00 to $150.00 and gave the company an equal weight rating in a report on Monday, May 6th. TD Cowen upped their target price on shares of DaVita from $139.00 to $150.00 and gave the company a hold rating in a report on Wednesday, July 24th. Truist Financial increased their price objective on shares of DaVita from $135.00 to $150.00 and gave the stock a hold rating in a report on Wednesday, May 15th. Finally, StockNews.com lowered shares of DaVita from a strong-buy rating to a buy rating in a report on Saturday, June 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, DaVita presently has a consensus rating of Hold and a consensus price target of $154.00.

DaVita Price Performance

NYSE DVA traded up $1.42 during trading hours on Wednesday, reaching $140.30. The company’s stock had a trading volume of 581,736 shares, compared to its average volume of 837,787. The stock has a market cap of $12.30 billion, a PE ratio of 15.94, a PEG ratio of 1.05 and a beta of 0.87. DaVita has a fifty-two week low of $71.51 and a fifty-two week high of $147.93. The company’s 50-day moving average is $139.96 and its two-hundred day moving average is $133.53. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 70.82%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.08 EPS. Analysts forecast that DaVita will post 9.62 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Blue Trust Inc. raised its holdings in DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after buying an additional 78 shares during the period. Wedmont Private Capital raised its holdings in DaVita by 6.0% in the second quarter. Wedmont Private Capital now owns 1,701 shares of the company’s stock valued at $241,000 after buying an additional 96 shares during the period. First Trust Direct Indexing L.P. raised its holdings in DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after buying an additional 98 shares during the period. Quent Capital LLC raised its holdings in DaVita by 21.0% in the first quarter. Quent Capital LLC now owns 581 shares of the company’s stock valued at $80,000 after buying an additional 101 shares during the period. Finally, GAMMA Investing LLC raised its holdings in DaVita by 18.8% in the first quarter. GAMMA Investing LLC now owns 657 shares of the company’s stock valued at $91,000 after buying an additional 104 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.